Summary Preliminary data from recent clinical radioimmunoscintigraphy studies indicate that 99mTc-labelled murine monoclonal antibodies (MAbs) E48 and U36 have a similar ability to target squamous cell carcinoma of the head and neck (HNSCC) selectively. In the present study we describe additional aspects of murine and chimeric MAb (mMAb and cMAb) E48 and U36, which might influence the selection of one MAb for adjuvant radioimmunotherapy. To make direct comparison possible, ten patients received 11.2 ± 0.3 and 11.1 ± 0.2 mg (n = 5) or 51.1 ± 0.1 and 51.0 ± 0.4 mg (n= 5) of both mE48 IgG and mU36 IgG labelled with 1311 and 1251 simultaneously and underwent surgery 7-8 days after injection. The mean uptake of iodine-labelled mE48 IgG and mU36 was highest in tumour tissue, 8.9 ± 8.9 and 8.2 ± 4.4 %ID kg-' respectively. Tumour to non-tumour ratios for oral mucosa, skin, muscle, blood and bone marrow aspirate were 2.5, 5.5, 25.2, 4.7 and 4.0 respectively in the case of mE48 IgG and 2.3, 4.1, 21.0, 5.8 and 5.8 respectively in the case of mU36 IgG. The distribution of mMAbs E48 and U36 throughout tumours that had been collected in previous studies was heterogeneous when administered at a dose of 1 or 12 mg, and homogeneous when administered at a dose of 52 mg. Administration of mE48 IgG (1-52 mg) resulted in a human anti-mouse antibody response in 12 out of 28 patients, while for mU36 IgG (1-52 mg), this figure was three out of 18 patients. cMAb E48 was shown to be highly effective in mediating antibody-dependent cellular cytotoxicity in vitro, while cMAb U36 and mMAbs E48 and U36 were not effective at all. Rationales are provided that give priority to the start of adjuvant radioimmunotherapy trials with 1'6Re-labelled cMAb U36 IgG in head and neck cancer patients who are at high risk for the development of locoregional recurrences and distant metastases.
During 1996 approximately 41 090 Americans will develop head and neck cancer and 12 510 will die from it. Worldwide more than 500 000 new cases are projected annually, and the incidence is rising. In head and neck cancer, squamous cell carcinoma accounts for approximately 90% of all tumours (Parker et al, 1996) . About one-third of these patients present with early-stage (I and II) head and neck squamous cell carcinoma (HNSCC), while two-thirds present with advanced disease (stage III and IV) (Vernham and Crowther, 1994) . Although early-stage HNSCC can, in the great majority of cases, be cured with surgery or radiotherapy alone, the local failure rate after surgery and/or radiotherapy in advanced stages is more than 50%. Moreover, about 25% of these patients develop distant metastases (Stupp et al, 1994) .
Despite an increase in the locoregional control of HNSCC, owing to improved surgery and radiotherapy, current therapy regimens have failed to increase the 5-year survival rate in HNSCC patients (Parker et al, 1996) . Whereas fewer patients tend to die from uncontrolled locoregional disease, more patients are exposed to the risk of developing distant metastases. Therefore, an effective systemic adjuvant therapy is needed. To date, there is no evidence that adjuvant chemotherapy has any survival benefit (Stell and Rawson, 1990) . Among the innovative approaches for improving the therapy of cancer is the use of monoclonal antibodies (MAbs). MAbs labelled with radionuclides offer the potential of highly localized radiation treatment of cancer (Goldenberg, 1989) . Radioimmunotherapy (RIT) may be particularly suitable for the treatment of HNSCC owing to the intrinsic radiosensitivity of this tumour type (Wessels et al, 1989) .
For effective adjuvant RIT, it is a requirement that the MAb shows a high and selective uptake as well as retention in all tumour deposits, including tumour nodules, malignant cell clusters and single tumour cells. When 1-emitters are used for RIT, it is not necessary that radiolabelled MAbs bind to each single cell within a tumour because of the cross-fire effect. Despite this, heterogeneous distribution of a radioimmunoconjugate throughout the tumour is unwanted in RIT because this can result in overkill in certain tumour areas, while leaving other areas relatively unaffected. When using chimerized, humanized or human MAbs in RIT, it can be anticipated that antibody-dependent cellular cytotoxicity (ADCC) may be supportive to irradiation, especially in eradicating single disseminated cells or small cell aggregates (Riethmuller et al, 1995) . For the most efficient mediation of ADCC, these MAbs should preferably contain a human yl constant region (Steplewski et al, 1988) . Such MAbs may also be less immunogenic than murine MAbs, which is of importance when repeated administrations are needed for effective therapy (Khazaeli et al, 1994 ).
For use in adjuvant RIT of HNSCC, we produced a panel of MAbs. Two of these MAbs, designated E48 and U36, are selectively reactive with normal and malignant squamous and transitional epithelia (Quak et al, 1990; Schrijvers et al, 1993 ). While MAb E48 shows a homogeneous reactivity with 70% of HNSCC, for MAb U36 this approaches 96% reactivity (De Bree et al, 1994a) . The biodistribution of 99mTc-labelled mE48 IgG and mU36 IgG has been evaluated by radioimmunoscintigraphy (RIS) and by biopsy measurement (De Bree et al, 1994b , 1995a in 24 and ten HNSCC patients respectively. Both MAbs were shown to be highly capable of selective tumour targeting in HNSCC patients, and the tumour uptake 2 days after injection was similarly high, 30 .6 + 20.1 %ID kg-' for mMAb E48 and 20.4 ± 12.4 %ID kg-1 for mMAb U36 (De Bree et al, 1995a,b) . Most recently, chimeric (mouse/human) E48 IgGi and U36 IgG, have been constructed (Brakenhoff et al, 1995) .
Data obtained from these studies justify the further development of one of these MAbs for adjuvant RIT. In this paper, we evaluate the potential of these MAbs for adjuvant therapy in a comparative way. To eliminate interindividual variations, mMAbs E48 and U36 were now administered simultaneously. Moreover, we used iodine labels to be able to assess the biodistribution of mMAbs at later time points. We report on (1) the biodistribution of simultaneously injected iodine-labelled mE48 IgG and mU36 IgG, 7-8 days after injection; (2) the distribution of the mMAbs throughout the tumour in relation to the administered MAb dose; (3) the immunogenicity of the mMAbs; and (4) the potential of the murine and chimeric versions of the MAbs to mediate ADCC. Based on our present and previous data, we come to a design for a first RIT trial in head and neck cancer patients.
MATERIALS AND METHODS

Monoclonal antibodies
MAb E48 was derived from a mouse immunized with cells from a metastasis of a moderately differentiated squamous cell carcinoma of the larynx. The antigen recognized by MAb E48 is a 16-to 22-kDa glycosylphosphatidylinositol-anchored membrane protein located on the outer cell surface (Quak et al, 1990) . The MAb E48-defined antigen was expressed in 94% of the primary HNSCCs (n = 196). In 70% of these tumours, the antigen was expressed by the majority of the cells within these tumours. A similar reactivity pattern was observed in 31 tumour-infiltrated lymph nodes from neck dissection specimens (De Bree et al, 1994a Before and up to 7 days after administration of the radioimmunoconjugates, urine and blood were obtained for analysis as described previously (De Bree et al, 1994b) . Vital signs were recorded before and up to 3 h after injection.
Radiolabelling of mE48 IgG and mU36 IgG mE48 IgG and mU36 IgG were prepared, purified and radiolabelled as described previously (De Bree et al, 1995a, b Pharmacokinetics Blood samples were obtained from the arm opposite to the injection site for the determination of activity up to 7-8 days p.i. Urine was collected over the first 48 h. Aliquots of blood and urine samples were measured for 13l1 and 125I activity in a well counter, compared with an aliquot retained from the conjugate preparation and corrected for decay. Blood activity was expressed as %ID kg-'.
High-performance liquid chromatography (HPLC) analysis of the serum samples revealed that more than 95% of the radioactivity was bound to the MAb. The pharmacokinetics was analysed modelling a time vs radioactivity curve for each infusion as described previously (De Bree et al, 1995a,b) . Excretion in the urine was expressed as the percentage of the injected dose in this period.
Bone marrow dosimetry Blood and whole-body data of both the 125I-and '3II-labelled mE48 IgG and mU36 IgG were used to calculate the marrow dose. The residence times of mMAb E48 and mMAb U36 in the blood and whole body were derived from numerical integration of the blood and urinary time activity curves. The blood and whole-body time activity curves were extrapolated to infinity using the decay factor between the last two measurement points. The activity in the whole body was assumed to be homogeneously distributed. No specific uptake in bone marrow was observed by RIS during the first days after injection. Therefore, the red marrow-blood activity ratio was assumed to be 0.3 (Siegel et al, 1990) . The red marrow dose was calculated according to MIRDDOSE2 (Watson and Stabin, 1984) . The red marrow dose was estimated from the kinetic data and a 131I label.
Statistical analysis
The Student's t-test for paired and unpaired data was used to determine the statistical significance of the difference between the uptake of mE48 IgG and mU36 IgG. Statistical difference was reached at P < 0.05.
Further characteristics of E48 IgG and U36 IgG
To obtain more information on the characteristics of E48 IgG and U36 IgG, data from this and previous studies with radiolabelled E48 IgG or U36 IgG alone were combined. The patient populations from previous studies have been described before (De Bree et al, 1994b , 1995a . In these studies, 19 patients received mE48 F(ab')2, nine patients received mE48 IgG, 15 patients received mE48 F(ab')2 as well as mE48 IgG, and ten patients received mU36 IgG.
Distribution of the MAbs throughout the tumour Cryosections were made from tumour biopsies obtained from patients included in previous studies (De Bree et al, 1995a,b) . These biopsies had been taken 2 days after injection of either mE48 IgG or mU36 IgG. The in vivo distribution of the injected MAb throughout the tumour was compared with the maximal MAb binding on serial sections. In short, 5-,um-thick sections of frozen tissue biopsies were cut on a cryostat microtome and mounted on poly-L-lysine-coated glass slides, dried, fixed in 2% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min and dried again.
To assess the distribution of the injected MAb throughout the tumour, the specimens were incubated for 30 min with rabbit antimouse IgG (Dako, Glostrup, Denmark) diluted 1:25 in PBS/1% normal rabbit serum/l% bovine serum albumin (BSA). The sections were washed three times with PBS and incubated for 1 h with alkaline phosphatase monoclonal anti-alkaline phosphatase (APAAP, Dako) diluted in PBS/1% BSA. The sections were washed again with PBS/1% BSA, rinsed with 0.1 M Tris, pH 8.2, and incubated in the dark for 20 min with naphthol AS-TR-phosphate/fast red violet British Journal of Cancer (1997) 75(7) (De Bree et al, 1994b , 1995a , and injected with mE48 F(ab')2, mE48 IgG, mU36 IgG or combinations thereof, are presented. The presence of human anti-mouse antibodies was tested in patients' sera before and 4-8 weeks after injection of radiolabelled mE48 F(ab')2 (group 1, n = 16); mE48 IgG (group 2, n = 5); mE48 F(ab')2 plus mE48 IgG (group 3, n = 13); mU36 IgG (group 4, n = 8); or mE48 IgG plus mU36 IgG (group 5, n = 10).
Fourteen patients in group 1 received 1 mg and two patients received 11 mg of mE48 F(ab')2. The Assay HAMA responses were analysed with an assay, essentially as described previously (Buist et al, 1995a) different effector-target (E:T) ratios ranging from 6.25:1 to 100:1 and MAbs were added to a final concentration of 10 pg ml-'. Plates were centrifuged at 65 x g for 30 s and incubated in 5% carbon dioxide at 37°C for 5 h after which medium was harvested from each well. All assays were performed in triplicate. Radioactivity was counted in a gamma-counter (1282 CompuGamma). Maximum radionuclide release was determined by incubation of target cells in the presence of 5% Triton X-100. Natural killer (NK) cell release (antibody-independent lysis) was measured by incubation of target-effector cells in the presence of the murine IgG, control anti-myosin MAb Myoscint (Centocor Inc.), which does not bind to the target cells. The percentage of specific lysis was calculated as the [(experimental release-background release)/(Triton release-background release)] x 100. Background release is defined as the release in the absence of specific antibody (= spontaneous release + NK release). Standard deviations were typically 0-8%.
RESULTS
Biodistribution of iodine-labelled mE48 and mU36 IgG simultaneously injected into ten HNSCC patients No adverse reactions were observed that could be related to the simultaneous injection of iodine-labelled mMAb E48 and mMAb U36. No significant changes were noted in blood and urine parameters except for TSH values. In three patients, TSH was found transiently below normal after injection. In one of these patients, TSH was already at the lower limit of normal before injection.
Free T3 increased in two of these patients to high levels. However, 
Radioimmunoscintigraphy with mMAbs E48 and U36
Whole-body images were obtained up to 3 (n = 2), 4 (n = 4), 6 (n = 2) and 8 (n = 1) days p. Biodistribution of mMAbs E48 and U36, 7-8 days after injection The activity uptake in biopsies from the surgical specimen is shown in Tables 2 and 3 . The mean uptake of iodine was the highest in tumour tissue: 8.9 8.9 %ID kg-' for iodine-labelled mE48 IgG and 8.2 4.4 %ID kg-' for iodine-labelled mU36 IgG. Table 2 shows that the variability in tumour uptake is smaller for mMAb U36 (range 2.9-15.2 %ID kg-') than for mMAb E48 (range 1.8-31.2 %ID kg-'). Moreover, it appears that in eight out of ten patients the tumour uptake of mU36 IgG was higher than the uptake of mE48 IgG. High uptake of the mMAb E48 and the mMAb U36 iodine labels was also seen in normal squamous epithelium of oral mucosa, tongue tissue and skin. These uptake levels were lower than in tumour tissue, but only significantly for mU36 IgG uptake in mucosa and tongue (P < 0.01 and P < 0.02 respectively). Tumour-positive lymph nodes contained more iodine than tumournegative nodes for mE48 IgG (P < 0.2, mean ratio 2.0 1.1) and mU36 IgG (P < 0.01, mean ratio 3.0 ± 1.2). Iodine uptake in other normal tissues was low, except for iodine-labelled mU36 IgG in glandular tissue. Low levels of activity were seen in bone marrow biopsies. Bone marrow aspirations showed mean iodine levels which were similar for mE48 IgG and mU36 IgG and almost similar to the activity levels in blood (mean bone marrow aspirate blood ratios of 0.9 0.0 and 1.0 ± 0.1 in the case of mE48 IgG and mU36 IgG respectively). The activity in the plasma of the bone marrow aspirate was higher than in the cellular sediment. The mean plasma activity in the bone marrow aspirate was slightly lower than in blood plasma; mean bone marrow aspirate plasma-blood plasma ratios were 0.9 ± 0.3 and 1.0 0.1 for mE48 IgG and mU36 IgG respectively.
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a Number of patients from whom biopsies were obtained. Figure 3 Primary tumour to non-tumour ratios of simultaneously injected iodine-labelled mE48 IgG (-) and mU36 (O) IgG in mucosa (Mc; n = 10), tongue (To; n = 5), skin (Sk; n = 5), positive lymph node (PL; n = 9), negative lymph node (NL; n = 10), muscle (Ms; n = 10), fat (Ft; n = 10), submandibular gland (Sm; n = 10), sublingual gland (SI; n = 1), vein (Ve; n = 7), bone marrow biopsy (BB; n = 6), total bone marrow aspiration (BA; n = 6), supernatant of bone marrow aspiration (Su; n = 6), sediment of bone marrow aspiration (Se; n = 6), blood (BI; n = 9) and plasma (PI; n = 9)
For iodine-labelled mE48 IgG, the mean tumour to non-tumour ratios varied between 1.8 for tongue and 34.2 for fat tissue, while for iodine-labelled mU36 IgG these values varied between 2.1 for sublingual gland and 28.7 for fat tissue (Figure 3 ). For mucosa, tongue, skin, submandibular gland, muscle, blood and bone marrow aspirate these ratios were 2.5, 1.8, 5.5, 9.8, 25.2, 4.7 There was also no significant difference in the excretion of iodine-labelled mE48 IgG and mU36 IgG in urine during the first 48 h: 23.0 ± 6.0 and 21.4 ± 5.1% of the injected dose respectively.
Bone marrow dosimetry Red marrow residence time and whole-body residence time were 4.1 ± 1.5 h and 85.5 ± 21.5 h respectively for mE48 IgG, and 4.3 ± 1.9 h and 88.5 ± 20.6 h respectively for mU36 IgG. The red marrow dose was calculated to be 1.89 ± 0.59 rad mCi-1 for 131I-labelled mE48 IgG and 2.00 + 0.75 for 13II-labelled mU36 IgG.
Further characteristics of E48 IgG AND U36 IgG Distribution of the mMAbs E48 and U36 throughout the tumour Distribution of MAbs throughout the tumour was analysed immunohistochemically in tumour biopsies obtained from patients who had been injected with either mE48 IgG or mU36 IgG alone (previous studies). Figure 4 shows typical mE48 IgG uptake in tumour biopsy specimens of three patients who had received 2, 12 and 52 mg of E48 IgG. Serial sections of each biopsy were incubated with rabbit anti-mouse IgG to demonstrate in vivo tumour uptake of mE48 IgG (sections A, C and E), or with mMAb E48 followed by rabbit antimouse IgG to demonstrate total E48 antigen expression, the maximum mE48 IgG binding (sections B, D and F) . After injection of 2 mg, a very heterogeneous distribution of mE48 IgG was observed. After injection of 12 mg of MAb, the distribution was much more homogeneous, while after injection of 52 mg almost all tumour cells were targeted by mE48 IgG. A similar distribution pattern was observed for mU36 IgG as illustrated for a tumour-infiltrated lymph node obtained from a patient who had received 52 mg of U36 IgG ( Figure 5 ). mE48 IgG or mU36 IgG could be detected in all tumour biopsies of patients who had received 12 or 52 mg of MAb; also in biopsies from tumour deposits not detected by RIS.
Immunogenicity of mMAbs E48 and U36
To assess the immunogenicity of MAbs mE48 and mU36, serum samples obtained from patients before and 4-8 weeks after injection of mE48 F(ab')2 (group 1), mE48 IgG (group 2), mE48 F(ab')2 plus mE48 IgG (group 3), mU36 IgG (group 4) and mE48 IgG plus mU36 IgG (group 5) were analysed for the presence of human anti-mouse antibodies (HAMA) with an in-house mE48 F(ab')2-, mE48 IgG-and/or mU36 IgG-related HAMA assay. Considering a HAMA titre of 2 500 to be positive, preMAb infusion samples were negative (HAMA titres < 50) for all patients (Figure 6 ). (1997) 75(7) Figure 6 Individual human anti-mouse antibody (HAMA) titres before and 4-8 weeks after injection of (A) mE48 F(ab')2, (B) mE48 IgG, (C) mE48 F(ab')2 plus mE48 IgG, (D ADCC assays with MAbs E48 and U36 revealed that spontaneous chromium release never exceeded 20%, while antibody-independent killing was less than 10%. When cMAb E48 was included in this assay at an effector-target ratio of 100: 1, specific lysis percentages of 62%, 72% and 96% were found respectively (Figure 7 ). For cMAb U36 these values were 1.2%, 5.2% and 3.5%, for mMAb E48 6%,11% and 17% and for mMAb U36 5.4%,3.0% and 4.7%. cMAb SF-25 served as a positive control in each ADCC assay and gave specific lysis percentages between 63% and 78% (data not shown).
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British Journal of Cancer (1997) 75(7) (De Bree et al, 1994a) ; all data are now available for the selection of one of these MAbs for adjuvant RIT and to estimate the feasibility of this therapeutic approach.
The most important requirement for a MAb to be used in adjuvant RIT is that the MAb should be capable of selective delivery of a sufficiently high dose of radioactivity to all tumour deposits, including tumour nodules, malignant cell clusters and single tumour cells. For 99mTc-labelled mMAb E48 and U36, we found mean tumour uptake levels of 30.6 and 20.4 %ID kg-' 2 days after injection (De Bree et al, 1995b) , while 7 days after injection the mean activity levels of iodine-labelled mMAb E48 and U36 in the tumour were still 8.9 and 8.2 %ID kg-'.
At our laboratory, an analogous 99mTc-and 1'6Re-labelling chemistry for MAbs directed to HNSCC has been developed, giving the option to use 99mTc and 186Re as a 'matched pair' for imaging, dosimetry calculations and therapy (Van Gog et al, 1996) . In these studies, a similar biodistribution of 1251 -, 1311 (Gerretsen et al, 1993) . In this animal model, RIT with 186Re-labelled mE48 IgG was more effective than RIT with I3'l-labelled mE48 IgG. When mice with xenografts of 75 mm3 were treated with 600 iCi of 186Re-labelled mE48 IgG, 100% complete remissions were observed (Gerretsen et al, 1994) . In these latter tumours, the mean absorbed dose was 85 Gy. Similar results were recently obtained with I86Re-labelled mU36 IgG in the same animal model (data not shown). These studies indicate that the decreased energy absorption in smaller tumours is compensated by the higher tumour uptake of MAbs. Also, recent results from clinical RIT studies using intraperitoneally administered 186Re-labelled NR-LU-10 IgG or '311-labelled MAb MOvl8 in adjuvant therapy of ovarian cancer patients showed that RIT may be particularly effective in eradicating minimal residual disease (Jacobs et al, 1993 , Crippa et al, 1995 . These dosimetry estimations indicate the feasibility of adjuvant RIT with radiolabelled E48 IgG or U36 IgG in head and neck cancer patients. However, these considerations are based on mean tumour uptake values and assume a uniform distribution of radioactivity throughout the tumour. It should be noted that for mMAb U36 the tumour uptake values show a large scatter, ranging from 8.0-43.0 %ID kg-' 2 days after injection, and from 2.9-18.2 %ID kg-' 7 days after injection. For mMAb E48 IgG, this scatter is even larger ranging from 7.2-82.3 %ID kg-' 2 days after injection, and 1.8-31.2 %ID kg-' 7 days after injection. It is not yet clear which patient and tumour characteristics influence tumour uptake of MAbs. Buist et al (1995b) analysed several tumour characteristics in ovarian cancer patients. Only antigen expression was proved to be related to tumour uptake. In HNSCC patients, antigen expression, tumour size and tumour site may influence tumour uptake (R de Bree et al, manuscript in preparation). Furthermore, it can be stated that heterogeneous distribution of a radioimmunoconjugate throughout the tumour is unwanted in RIT because this can result in overkill in certain tumour areas, while leaving other areas relatively unaffected. In the present study, we show that the distribution of mMAb E48 and U36 becomes more homogeneous when a higher MAb dose is administered; a phenomenon also observed in other preclinical and clinical studies (Blumenthal et al, 1991; Oosterwijk et al, 1993) . With respect to this, a MAb dose of about 50 mg is recommended for future RIT studies because this dose resulted in homogeneous distribution throughout the tumour. A much higher MAb dose will result in saturation of antigenic sites, while other disadvantages are related to costs and possibly to the immunogenicity of the MAb.
Although uptake of mE48 IgG and mU36 IgG was highest in tumour tissue, 2 as well as 7 days after injection, there was also high uptake in normal squamous epithelia, such as oral mucosa, tongue and skin, which can be explained by the presence of antigen in these tissues. However, it can be calculated from the biodistribution data that the absorbed dose for large tumours will on average be twice that of normal squamous epithelia. In adjuvant therapy this difference may be larger owing to the higher MAb uptake in small tumours. In that case anti-tumour effects can be expected with limited toxic side-effects caused by concomitant irradiation of normal squamous epithelium.
Uptake at non-tumour sites, especially the bone marrow, should be considered, since bone marrow has been identified as the doselimiting organ in RIT. Data on bone marrow dosimetry indicate that the radiation dose delivered to the bone marrow by mE48 IgG or mU36 IgG is similar.
It may be beneficial for a MAb used for RIT to have ADCCmediating potential. ADCC, by helping to eradicate single disseminated cells or cell aggregates, may be additive to radiation effects. We showed that E48 IgG was highly effective in mediating ADCC when the murine yI region was substituted for the human yl constant region. Unfortunately, we have not been able to demonstrate any ADCC-mediating capacity of cMAb U36. Cloning strategies and expression vectors used for the construction of cMAb U36 and cMAb E48 were the same. In contrast, host cells used for transfection were different for both cMAbs. The ADCC assay developed for evaluating cMAb E48 had to be adapted for cMAb U36 owing to the sensitivity of the U36 antigen for trypsin treatment. It is unlikely, however, that these factors are responsible for the ineffectiveness of cMAb U36 in ADCC assays. A more likely explanation is that the epitope recognized by MAb U36, recently identified as being part of CD44v6, is not a favourable target epitope for ADCC (Van Hal et al, in press ). Mediation of ADCC via the MAb Fc regions is dependent on the distance between Fc tails, and this distance may be related to the epitopes recognized.
In general, immunogenicity of a MAb is only a problem when the MAb is administered repeatedly. Although uncommon, adverse reactions like anaphylactic reactions can occur (Riethmuller et al, 1994) . Furthermore, rapid clearance of infused MAb will occur upon subsequent administrations resulting in a diminished targeting efficiency of the MAb to the tumour (Khazaeli et al, 1994) . In the present study, mU36 IgG appeared to be less immunogenic than E48 IgG. Up to now just three of 18 patients receiving 1-52 mg of mU36 IgG have shown a HAMA response when measured in the mU36 IgG-related HAMA assay, and this frequency may fall when cU36 IgG is used in RIT studies.
In this and previous papers, we have shown biodistribution data indicating that mE48 IgG and mU36 IgG are equally well suited for targeting antigen-positive tumour deposits. Because of its more homogeneous reactivity pattern, however, we think that MAb U36 is more generally applicable and therefore more suitable for RIT than MAb E48. Based on the aforementioned considerations, we will give priority to a phase I RIT trial with 186Re-labelled cU36 IgG in head and neck cancer patients with inoperable local or regional recurrences or distant metastases. In this radiation dosefinding study, patients will receive a single injection of the radioimmunoconjugate at a protein dose of 50 mg. When 186Re-labelled cU36 IgG is well tolerated and dosimetry estimations show the feasibility of RIT, an adjuvant RIT trial will be started.
